Switch theme
Sign up to access all valuation multiples
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany, Austria, Netherlands, and Switzerland.
2004
602
LTM Revenue $77.6M
LTM EBITDA -$24.9M
$472M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Allergy Therapuetics has a last 12-month revenue (LTM) of $77.6M and a last 12-month EBITDA of -$24.9M.
In the most recent fiscal year, Allergy Therapuetics achieved revenue of $74.1M and an EBITDA of -$41.3M.
Allergy Therapuetics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Allergy Therapuetics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $77.6M | XXX | $74.1M | XXX | XXX | XXX |
| Gross Profit | $77.6M | XXX | $39.9M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | -$24.9M | XXX | -$41.3M | XXX | XXX | XXX |
| EBITDA Margin | -32% | XXX | -56% | XXX | XXX | XXX |
| EBIT | -$32.0M | XXX | -$45.7M | XXX | XXX | XXX |
| EBIT Margin | -41% | XXX | -62% | XXX | XXX | XXX |
| Net Profit | -$44.7M | XXX | -$54.0M | XXX | XXX | XXX |
| Net Margin | -58% | XXX | -73% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $13.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Allergy Therapuetics's stock price is GBP 0 (or $0).
Allergy Therapuetics has current market cap of GBP 329M (or $442M), and EV of GBP 352M (or $472M).
See Allergy Therapuetics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $472M | $442M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Allergy Therapuetics has market cap of $442M and EV of $472M.
Allergy Therapuetics's trades at 6.2x EV/Revenue multiple, and -14.6x EV/EBITDA.
Equity research analysts estimate Allergy Therapuetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Allergy Therapuetics has a P/E ratio of -9.9x.
See valuation multiples for Allergy Therapuetics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $442M | XXX | $442M | XXX | XXX | XXX |
| EV (current) | $472M | XXX | $472M | XXX | XXX | XXX |
| EV/Revenue | 6.1x | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBITDA | -19.0x | XXX | -14.6x | XXX | XXX | XXX |
| EV/EBIT | -14.7x | XXX | -12.3x | XXX | XXX | XXX |
| EV/Gross Profit | 6.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.9x | XXX | -9.0x | XXX | XXX | XXX |
| EV/FCF | -14.8x | XXX | -12.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAllergy Therapuetics's last 12 month revenue growth is 31%
Allergy Therapuetics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Allergy Therapuetics's rule of 40 is -27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Allergy Therapuetics's rule of X is 44% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Allergy Therapuetics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 31% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -32% | XXX | -43% | XXX | XXX | XXX |
| EBITDA Growth | -60% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -27% | XXX | -12% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 44% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 41% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 116% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Allergy Therapuetics acquired XXX companies to date.
Last acquisition by Allergy Therapuetics was XXXXXXXX, XXXXX XXXXX XXXXXX . Allergy Therapuetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Allergy Therapuetics founded? | Allergy Therapuetics was founded in 2004. |
| Where is Allergy Therapuetics headquartered? | Allergy Therapuetics is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Allergy Therapuetics have? | As of today, Allergy Therapuetics has 602 employees. |
| Who is the CEO of Allergy Therapuetics? | Allergy Therapuetics's CEO is Mr. Manuel Llobet. |
| Is Allergy Therapuetics publicy listed? | Yes, Allergy Therapuetics is a public company listed on LON. |
| What is the stock symbol of Allergy Therapuetics? | Allergy Therapuetics trades under AGY ticker. |
| When did Allergy Therapuetics go public? | Allergy Therapuetics went public in 2004. |
| Who are competitors of Allergy Therapuetics? | Similar companies to Allergy Therapuetics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Allergy Therapuetics? | Allergy Therapuetics's current market cap is $442M |
| What is the current revenue of Allergy Therapuetics? | Allergy Therapuetics's last 12 months revenue is $77.6M. |
| What is the current revenue growth of Allergy Therapuetics? | Allergy Therapuetics revenue growth (NTM/LTM) is 31%. |
| What is the current EV/Revenue multiple of Allergy Therapuetics? | Current revenue multiple of Allergy Therapuetics is 6.1x. |
| Is Allergy Therapuetics profitable? | Yes, Allergy Therapuetics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Allergy Therapuetics? | Allergy Therapuetics's last 12 months EBITDA is -$24.9M. |
| What is Allergy Therapuetics's EBITDA margin? | Allergy Therapuetics's last 12 months EBITDA margin is -32%. |
| What is the current EV/EBITDA multiple of Allergy Therapuetics? | Current EBITDA multiple of Allergy Therapuetics is -19.0x. |
| What is the current FCF of Allergy Therapuetics? | Allergy Therapuetics's last 12 months FCF is -$32.0M. |
| What is Allergy Therapuetics's FCF margin? | Allergy Therapuetics's last 12 months FCF margin is -41%. |
| What is the current EV/FCF multiple of Allergy Therapuetics? | Current FCF multiple of Allergy Therapuetics is -14.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
